湖北均瑶大健康饮品股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 26 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 301,094,315 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 70.0219 | 证券代码：605388 证券简称：均瑶健康 公告编号：2024-033 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董 事会召集，本次会议现场由董事长王均豪先生主持，采用现场与网络投票相结合 的方式召开。本次会议的召集、召开和表决方式符合《公司法》等法律法规和《公 (一) 股东大会召开的时间：2024 年 5 月 9 日 (二) 股东大会召开的地点：上海市浦东新区康桥东路 2 弄 1 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2024-032 湖北均瑶大健康饮品股份有限公司 截至 2024 年 4 月 30 日，公司通过集中竞价交易方式累计回购股份数量 3,740,000 股，占公司总股本的比例为 0.870%，购买的最高价为人民币 9.34 元/股， 最低价为人民币 7.63 元/股，已支付的总金额为人民币 32,653,431.46 元（不含交 易费用）。 上述股份回购进展符合既定的回购股份方案。 三、 其他事项 | 回购方案首次披露日 | 2024/2/20 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 2 月 年 2 月 | 19 | 日~2025 | 18 | 日 | | 预计回购金额 | 元 100,000,000 元~200,000,000 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 股 ...

湖北均瑶大健康饮品股份有限公司 二〇二三年年度股东大会会议资料 湖北均瑶大健康饮品股份有限公司 二〇二三年年度股东大会 会议资料 湖北均瑶大健康饮品股份有限公司 二〇二三年年度股东大会会议资料 目 录 | 会议须知 3 | | | | --- | --- | --- | | 会议议程 5 | | | | 议案一：关于 | 2023 | 年度董事会工作报告的议案 7 | | 议案二：关于 | 2023 | 年度监事会工作报告的议案 8 | | 议案三：关于 | 2023 | 年度财务决算报告的议案 9 | | 议案四：关于 | 2023 | 年度利润分配及资本公积金转增股本预案的议案 10 | | 议案五：关于公司 | 2023 | 年年度报告及摘要的议案 12 | | 议案六：关于公司董事及监事薪酬方案的议案 13 | | | | 议案七：关于预计公司 | 2024 | 年日常关联交易的议案 15 | | 议案八：关于使用部分闲置自有资金进行现金管理暨关联交易的议案 16 | | | | 议案九：关于使用部分自有资金开展金融服务业务暨关联交易的议案 17 | | | | 议案十：关于修订《公司章程》并办理工商 ...

湖北均瑶大健康饮品股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605388 证券简称：均瑶健康 公告编号：2024-031 重要内容提示： 会议召开时间：2024 年 5 月 27 日（星期一）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 投资者可于 2024 年 5 月 24 日(星期五)16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2024 年 4 月 19 日披露《公司 2023 年度报告》，于 2024 年 4 月 26 日披露《公司 2024 年第 一季度报告》，为便于广大投资者更全面深入地 ...

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company achieved a revenue of 1.634 billion yuan in 2023, representing a growth of 65.7%, but the net profit attributable to the parent company decreased by 24.9% to 57.58 million yuan [16]. - In Q1 2024, the company reported a revenue of 400 million yuan, a decline of 11.1%, while the net profit attributable to the parent company increased by 9.3% to 30 million yuan [16]. - The integration of Yunyang Runying and the supply chain of Fan Yuan has shown positive effects, with significant revenue growth in various segments [16]. - The company plans to distribute a cash dividend of 0.10 yuan per share and a capital reserve conversion of 0.4 shares per share [16]. Financial Performance Summary - Revenue projections for 2024-2026 are 1.902 billion yuan, 2.253 billion yuan, and 2.587 billion yuan, with growth rates of 16.4%, 18.4%, and 14.8% respectively [2]. - The net profit attributable to the parent company is expected to be 78.10 million yuan, 102.88 million yuan, and 134.49 million yuan for the years 2024-2026, with growth rates of 35.6%, 31.7%, and 30.7% respectively [2]. - The earnings per share (EPS) are projected to be 0.18 yuan, 0.24 yuan, and 0.31 yuan for 2024-2026 [2]. Business Segment Analysis - Probiotics beverage sales are expected to maintain a growth rate of 3% from 2024 to 2026, with price increases anticipated [6]. - The probiotics food segment is projected to see significant growth, with sales growth rates of 85%, 80%, and 40% for 2024-2026, maintaining stable pricing and high gross margins [34]. - The supply chain business is expected to grow at rates of 13%, 10%, and 10% from 2024 to 2026, with a consistent gross margin of 10% [20]. Profitability Metrics - The gross margin for 2023 was 24.4%, with an increase to 29.5% in Q1 2024, indicating a recovery in profitability [16]. - The net profit margin for 2023 was 4%, which improved to 6.5% in Q1 2024 [16]. - The report highlights the impact of business restructuring on profitability, with expectations for gradual recovery as new products are launched and prices are adjusted [16].

Investment Rating - The report maintains a "Buy" investment rating for the company [20]. Core Views - The company has shown significant improvement in profitability, with successful overseas expansion efforts [19]. - The first quarter of 2024 saw a total revenue of 396 million yuan, a year-on-year decrease of 11%, while the net profit attributable to shareholders increased by 9% to 26 million yuan [19]. - The gross margin improved by 7 percentage points to 29.50%, indicating effective cost structure optimization [19]. - The probiotic business continues to develop, with notable growth in overseas markets [19]. Financial Forecasts - The company's main revenue is projected to grow from 1,634 million yuan in 2023 to 3,047 million yuan by 2026, with growth rates of 65.7%, 28.5%, 22.8%, and 18.1% respectively [2][30]. - The net profit attributable to shareholders is expected to rise from 58 million yuan in 2023 to 233 million yuan in 2026, with growth rates of -24.9%, 114.0%, 39.0%, and 36.3% respectively [2][30]. - The diluted earnings per share (EPS) is forecasted to increase from 0.13 yuan in 2023 to 0.54 yuan in 2026 [2][30]. - The return on equity (ROE) is anticipated to improve from 3.0% in 2023 to 11.4% in 2026 [2][30].

证券代码：605388 证券简称：均瑶健康 公告编号：2024-030 湖北均瑶大健康饮品股份有限公司 关于 2023 年年度股东大会会议通知的更正补充公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 1. 原股东大会的类型和届次： 2023 年年度股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 605388 | 均瑶健康 | 2024/4/29 | 二、 更正补充事项涉及的具体内容和原因 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日在上海证券交易所网站（www.sse.com.cn）上披露了《湖北均瑶大健康饮品股 份有限公司关于召开 2023 年年度股东大会的通知》（公告编号：2024-027）。原 披露公告中有部分内容需予以修正，相关内容如下： 修正前： | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 395,905,330.07, representing a decrease of 11.10% compared to the same period last year[5]. - Net profit attributable to shareholders of the listed company was CNY 26,150,321.80, an increase of 9.34% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 23,794,077.50, reflecting a growth of 28.20% compared to the previous year[5]. - The basic earnings per share for the period remained at CNY 0.06, unchanged from the previous year[5]. - In Q1 2024, the company's net profit reached CNY 25,691,096.53, a slight increase from CNY 25,089,016.23 in Q1 2023, representing a growth of 2.4%[24]. - The total revenue for Q1 2024 was CNY 34,518,629.33, compared to CNY 33,477,682.25 in Q1 2023, indicating a year-over-year increase of 3.1%[24]. - Operating profit for Q1 2024 was CNY 34,344,130.23, up from CNY 33,559,160.01 in the same period last year, reflecting a growth of 2.3%[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,287,357,753.55, down 8.60% from the end of the previous year[6]. - The total assets as of March 31, 2024, were CNY 2.29 billion, a decrease of 8.6% from CNY 2.50 billion as of December 31, 2023[19]. - The total liabilities decreased to CNY 354.27 million in Q1 2024, down 37.9% from CNY 569.85 million in Q4 2023[20]. - The company's total equity as of March 31, 2024, was CNY 1.93 billion, slightly up from CNY 1.93 billion at the end of 2023[21]. Cash Flow - The net cash flow from operating activities was negative at CNY -129,488,834.36, with no applicable percentage change due to the nature of the data[5]. - The cash flow from operating activities showed a net outflow of CNY -129,488,834.36 in Q1 2024, worsening from CNY -92,212,326.92 in Q1 2023[28]. - Cash and cash equivalents at the end of Q1 2024 were CNY 225,990,046.68, down from CNY 347,527,068.94 at the end of Q1 2023[29]. - The company reported a significant decrease in cash received from sales, totaling CNY 301,006,032.17 in Q1 2024, compared to CNY 435,936,870.69 in Q1 2023, a decline of 30.9%[27]. - Investment activities resulted in a net cash outflow of CNY -78,431,446.71 in Q1 2024, compared to CNY -225,900,560.30 in Q1 2023, showing an improvement in cash flow management[28]. - The total cash outflow from financing activities was CNY 25,738,935.67 in Q1 2024, compared to CNY 1,510,000.00 in Q1 2023, indicating increased financing costs[29]. Shareholder Information - The top ten shareholders held a total of 32.66% and 24.18% of shares, respectively, with significant pledges on their holdings[10]. - The company's repurchase account holds 2,850,000 shares, accounting for 0.66% of the total share capital as of the reporting period[12]. Business Strategy and Development - The company integrated the domestic probiotic leader Junyao Runying, aiming to transform its business model over the next three to five years[14]. - The company is focusing on optimizing and upgrading existing products to enhance product strength and market competitiveness[13]. - The company is committed to becoming a global leader in probiotics, with a strategic vision to break the foreign monopoly in fermented food and beverages[13]. - The company has established a comprehensive "R&D-production-sales" integrated chain in the probiotic industry, facilitating effective industry layout[12]. - The company’s traditional business of ambient yogurt continues to expand its product categories and optimize existing products[15]. - The company’s probiotic business has shown significant growth, driven by capacity enhancement and competitive advantages in overseas markets[12]. - The company has developed a unique production process for its ambient lactic acid bacteria beverages, enhancing its competitive edge in the market[16]. - The company is focusing on the promotion and application of proprietary functional strains, which is expected to drive product upgrades and optimize overall business competitiveness[16]. Research and Development - The company's R&D expenses increased to CNY 7.33 million in Q1 2024, up 88.5% from CNY 3.88 million in Q1 2023, indicating a strong focus on innovation[23]. - The company's fermentation agent production line has been selected for the 2023 Shanghai Dairy Industry Advantageous Characteristic Industry Cluster Project[15]. Profitability and Cost Management - The company has enhanced its product cost structure, resulting in a noticeable recovery in gross profit margin compared to 2023[15]. - The total operating costs for Q1 2024 were CNY 363.85 million, down 13.2% from CNY 419.22 million in Q1 2023[23]. - The weighted average return on net assets increased by 0.10 percentage points to 1.34%[5].

Investment Rating - The report maintains a "Buy" investment rating for Junyao Health (605388.SH) [2][3] Core Views - The company has shown robust revenue growth with a total revenue of 1.634 billion yuan in 2023, representing a 66% increase, primarily driven by exclusive patented technologies and new product developments [2][3] - The net profit attributable to shareholders was 58 million yuan, a decrease of 25% due to the timing of the 2024 Spring Festival affecting Q4 sales [2][3] - The report highlights the potential for profit recovery in 2024, with expectations of improved gross margins as raw material costs decline [3] Revenue and Profitability - The total revenue for Q4 2023 was 278 million yuan, a 97% increase year-on-year, but the net profit was negative at -25 million yuan, compared to -2 million yuan in the same period of 2022 [2][3] - The gross margin for 2023 was reported at 24.43% for the year and 22.91% for Q4, reflecting a decrease due to rising raw material costs and market fluctuations [2][3] - The company’s sales and management expense ratios were 11.49% and 7.76%, respectively, both showing a reduction, which contributed to a net profit margin of 3.96% [2][3] Product and Market Performance - The report notes that the lactic acid beverage segment faced short-term pressure, with revenue of 580 million yuan, down 11% year-on-year, due to market fatigue and increased competition [2][3] - The probiotic food segment saw significant growth, with revenue of 155 million yuan, up 206%, largely due to the consolidation of Runying [2][3] - The supply chain business contributed to new growth points, with revenue of 809 million yuan, a 463% increase, benefiting from improved business collaboration and standardization [2][3] Future Outlook - The report projects EPS for 2024-2026 to be 0.29, 0.40, and 0.54 yuan, respectively, with corresponding PE ratios of 28, 20, and 15 times [3] - The company is expected to achieve a revenue target of 400 million yuan for Runying in 2024, contingent on successful order fulfillment [2][3] - The report emphasizes the company's leading position in the ambient lactic acid bacteria industry, enhanced by proprietary core functional strains [3]